EAU20 Virtual

https://conferences.medicom-publishers.com/wp-content/uploads/2024/04/ACC.24-podcast-1.mp3Welcome to today’s podcast, covering American College of Cardiology Scientific Sessions & Expo. From 6–8 April 2024, in Atlanta, Georgia, over 17,000 cardiovascular professionals from around the globe came together to debate and discuss practice-changing science and innovations. Today, I was able to interview 2 of the late-breaking trialists.Firstly, we speak with Prof. Gregg Stone, MD, a professor of cardiology…

There are a multitude of treatment options available for patients with newly diagnosed multiple myeloma. However, many patients relapse following their first-line treatment and will require subsequent therapy. Dr Francesca Gay (University of Torino, Italy) discussed available therapies in the second line and beyond, as well as factors which can be used for treatment selection.Based on available treatment guidelines [2,3],…

Immunotherapies represent the bulk of recently approved agents for multiple myeloma. Dr Rakesh Popat (University College London Hospitals, UK) discussed upcoming treatment regimens characterised by cereblon E3 ligase modulatory drugs (CELMoDs) and the resurgence of belantamab mafodotin as a triplet combination [1].The CELMoD iberdomide was assessed as a doublet with dexamethasone in the phase 1/2 CC-220-MM-001 trial, leading to overall…

CAR T-cell therapies and bispecific antibodies have shown high response rates in patients with relapsed/refractory multiple myeloma. Dr Alfred Garfall (University of Pennsylvania, PA, USA) discussed efficacy, toxicities, and combination approaches of currently available CAR T-cell therapies and bispecific antibodies [1].In terms of logistics and administration, CAR T-cell therapies require a dedicated cellular therapy centre, a manufacturing slot, and extended…

Immunotherapies have changed the treatment of relapsed/refractory multiple myeloma with 5 agents now approved based on positive results from clinical trials. “As always in myeloma, trial results are overtaken by the changing treatment landscape,” said Dr Elias K. Mai (University Hospital Heidelberg, Germany). In his opinion, “we should not expect a ‘cure’ with single-shot treatment, and we need academic studies…

A total of 6 novel therapies are approved for relapsed/refractory multiple myeloma, including 2 CAR T-cell products (ide-cel and cilta-cel), 3 bispecific antibodies (teclistamab, elranatamab, and talquetamab), and 1 antibody-drug conjugate (belantamab mafodotin, now with conditional approval rescinded). Dr Nizar Bahlis (University of Calgary, Canada) presented mechanisms of resistance to CAR T-cell and bispecific antibody therapies.“When we think about mechanisms…

Dear Colleagues,The AAD 2024 in San Diego was a meeting with broad information on innovations in Dermatology. In this introduction, I highlight two major leads in dermatology innovations at AAD 2024.JAK inhibitors have a major impact on inflammatory skin diseases. A phase 2 trial showed that upadacitinib (a JAK1 inhibitor) led to a fast improvement in repigmentation in vitiligo. Povorcitinib…

Comparing paediatric patients with atopic dermatitis (AD) to a healthy reference population found a lower mean height and a higher mean weight in those affected with AD. For example, among the boys, 38% and 69% were above the 50th percentile for height and body mass index (BMI).PEDISTAD (NCT03687359) is a prospective 10-year observational study assessing paediatric patients aged <12 years…

For venous thromboembolic (VTE) events, serious infections, and malignancies, except for non-melanoma skin cancer (NMSC), no significant differences in incidence rates of long-term adverse events were detected during treatment with JAK inhibitors versus non-JAK agents. The only observed disadvantage of the JAK inhibitors was a significantly higher incidence rate of herpes zoster infections. Yet, the incidence rates for NMSC and…

Patients with alopecia areata (AA) continued to show a response to therapy in a long-term extension of the BRAVE-AA studies. Over 80% of responders to therapy with baricitinib at week 52 maintained their response until week 152. In severe AA, the disease tends to run a chronic course that often requires long-term therapy [1]. Moreover, it considerably affects quality-of-life, particularly…